Dr. Pierre Maison-Blanche

Education

Faculté de Médecine Paris 7
Assistance Publique des Hôpitaux de Paris

Certification

Board certified in Medecine : 1981
Board certified in Cardiology : 1986

Graduate Medical training

Fellowship : Cardiology
Hôpital Lariboisière, Service de Cardiologie (Pr Bouvrain, Pr Slama, Pr Coumel)
1981-1986

Primary affiliation: Centre Médico Chirurgical Ambroise Paré

Department : Cardiology
Address : 25, Boulevard Victor Hugo
Post Code/Zip : 92300
City : Neuilly sur Seine
Primary conditions
Abnormal Heart Rhythm (Arrhythmias), Atrial Fibrillation (AFib), Cardiomyopathy
Primary treatments
Ambulatory Cardiac Monitoring, Electrophysiology Study, Catheter ablation of cardiac arrhythmias, Implantable Cardioverter Defibrillator Insertion, Insertion of Pacemakers
6 Secondary affiliation (Academic)

1981-2009

Consultant Physician
Department : Cardiology
Hôpital Lariboisière
Post code/zip 75010
City : Paris
Primary conditions
Abnormal Heart Rhythm (Arrhythmias), Atrial Fibrillation (AFib), Cardiomyopathy
Primary treatments
Ambulatory Cardiac Monitoring

2009-Present

Consultant Physician
Department : Cardiology
Hôpital Bichat
Post code/zip 75018
City : Paris
Primary conditions
Abnormal Heart Rhythm (Arrhythmias), Atrial Fibrillation (AFib), Cardiomyopathy
Primary treatments
Ambulatory Cardiac Monitoring

General Curriculum Vitae

Dr Pierre Maison-Blanche earned an MD at the University of Paris in 1981 and trained in Cardiology at the University of Paris at Lariboisière Hospital. He served in Cardiology at Lariboisière Hospital and then at Bichat Hospital for more than 35 years where he performed cardiac angiography, clinical research in the cardiovascular area. Since 25 years his clinical speciality is non-invasive electrophysiology and he organized the ECG laboratory at Lariboisière Hospital under the leadership of Pr Philippe Coumel.
Dr Maison-Blanche still serves as a Consultant for Assistance Publique des Hôpitaux de Paris, Hôpital Bichat, Cardiology Unit. He is a Fellow of the French Society of Cardiology. He is acting as an independent consultant to a number of ECG manufacturers, ECG central laboratories, and Pharmaceutical companies. He is also a full Member of the Cardiac Safety Research Consortium (CSRC) launched in 2006 by FDA with Duke University to support research into the evaluation of cardiac safety of medical products.
In 1998, Maison-Blanche established the Centralized ECG Services Department for MDS Pharma Services in Paris, France, and chaired the MDS ECG Advisory Board from 2002 to 2006. He formerly was appointed as Biomedical Systems Chief Medical Officer from 2007 to 2012, Saint Louis, USA. From 2013 to 2016, Dr Maison-Blanche serves as the Cardiabase Chief Medical Officer, Nancy, France. Dr Maison-Blanche has participated in several End of Phase II meetings with the Food and Drug Administration (FDA) as well as in Advisory Boards as an active member (Anti infective, Urologic AD). He is currently a member or the Chairman of
• Safety Advisory Committees for Phase 1 trials (FIH, SAD and MAD)
• End point Adjudication Committee (Anti arrhythmic and device detected arrhythmias)
• MACE Adjudication Committees (COPD, Asthma)
• Data Monitoring Committees for Phase 3 pivotal trials (CNS, COPD, Asthma, Oncology).

Publications

Pierre Maison-Blanche has authored or co-authored 119 peer reviewed papers, see Pubmed

2017 and 2018 Publications

Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs
Paul Kligfield, MD, Fabio Badilini, PhD, Isabelle Denjoy, MD, Saeed Babaeizadeh, PhD, Elaine Clark, MA, Johan De Bie, PhD, Brian Devine, MSc, Fabrice Extramiana, MD, Gianluca Generali, Richard Gregg, MS, Eric Helfenbein, MS, Jan Kors, MSc, PhD, Remo Leber, MSc, Peter Macfarlane, DSc, Pierre Maison-Blanche, MD, Ian Rowlandson, MS, Ramun Schmid, MSc, Martino Vaglio, MS, Gerard van Herpen, MD, PhD, Joel Xue, PhD, Brian Young, Cynthia L. Green, PhD
Am Heart Journal, June 2018, 200, Pages 1–10

Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Mistry PK, Balwani M, Baris HN, Turkia HB, Burrow TA, Charrow J, Cox GF, Danda S, Dragosky M, Drelichman G, El-Beshlawy A, Fraga C, Freisens S, Gaemers S, Hadjiev E, Kishnani PS, Lukina E, Maison-Blanche P, Martins AM, Pastores G, Petakov M, Peterschmitt MJ, Rosenbaum H, Rosenbloom B, Underhill LH, Cox TM.
Blood Cells Mol Dis. 2018 Jul ;71:71-7

Non-clinical cardiovascular safety of pitolisant : comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
Ligneau X, Shah RR, Berrebi-Bertrand I, Mirams GR, Robert P, Landais L, Maison-Blanche P, Faivre JF, Lecomte JM, Schwartz JC.
Br J Pharmacol. 2017 Dec ;174(23):4449-4463

Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Belmatoug N, Di Rocco M, Fraga C, Giraldo P, Hughes D, Lukina E, Maison-Blanche P, Merkel M, Niederau C, Plӧckinger U, Richter J, Stulnig TM, Vom Dahl S, Cox TM.
Eur J Intern Med. 2017 Jan ;37 :25-32

Go back to previous page